PDQ-8 and ADL worsened in standard-of-care medication group, remained stable in stimulation group<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 22, 2024 (HealthDay News) — For patients with Parkinson disease (PD), differences in quality of life (QOL) outcomes are seen with deep brain stimulation of the subthalamic nucleus (STN-DBS), according to a study published online Jan. 18 in JAMA Network Open<\/em>.<\/p>\n Stefanie T. Jost, Ph.D., from the University of Cologne in Germany, and colleagues examined the long-term effects of STN-DBS versus standard-of-care medication (MED) on QOL in a prospective observational, quasi-experimental trial involving patients with PD. Overall, 108 patients underwent propensity score-matching (62 in the STN-DBS group and 46 in the MED group), resulting in a well-balanced matched subcohort with 25 patients in each group.<\/p>\n The researchers found that Parkinson’s Disease Questionnaire 8 (PDQ-8) and activities of daily living (ADL) worsened only in the MED group at five-year follow-up (PDQ-8 change, \u00e2\u0088\u009210.9; ADL change, \u00e2\u0088\u00922.0), while in the STN-DBS group, both outcomes remained stable. There was a moderate correlation observed for changes in PDQ-8 and ADL. STN-DBS outcomes were favorable for motor complications, mobility, and levodopa-equivalent daily dose reduction (mean differences in change scores between STN-DBS and MED, \u00e2\u0088\u00922.0, \u00e2\u0088\u00921.0, and \u00e2\u0088\u0092821.4, respectively).<\/p>\n “These findings may provide helpful information when counseling patients on the efficacy of STN-DBS for PD and monitoring patients postoperatively in long-term follow-up,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n